What’s Hot in Boston Biotech? Here’s the Agenda

Join us April 8 at What's Hot in Boston Biotech!

There’s just a few weeks left before our annual biotech extravaganza in Boston.

On April 8, we’ll be hosting “What’s Hot in Boston Biotech” at the Broad Institute of MIT and Harvard in Cambridge. We’ve put together a big lineup of executives, scientists, entrepreneurs, and investors across some of the hottest fields of life sciences research—from gene therapy to neuroscience to cell therapy,to the good and bad microbes in your gut—for a series of lively, interactive discussions and panels.

Here are just a few of the speakers you can expect to see:

—David Altshuler: Executive VP of Global Research and CSO, Vertex Pharmaceuticals

—Noubar Afeyan: Managing Partner and CEO, Flagship Ventures

—Tony Coles: CEO, Chairman and Founding Investor, Yumanity Therapeutics

—James Collins: Termeer Professor of Medical Engineering & Science, MIT

—Olivier Danos: Senior Vice President, Gene Therapy, Biogen

—Susan Lindquist: Member, Whitehead Institute, Scientific Founder, Yumanity Therapeutics

—Marian Nakada: VP of Venture Investments, Johnson & Johnson Innovation

We’ve just posted the agenda for the event here. If you don’t have your ticket yet, there are still a few spots up for grabs—you can register here. Just like last year, it’ll be a packed house. See you all on April 8.

Author: Ben Fidler

Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.